Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 4, 2005, Pages 1617-1621

  Razonable, Raymund R ^a,b,c   Henault, Martin ^b   Lee, Linda N ^b   Laethem, Carmen ^b   Johnston, Paul A ^b   Watson, Harold L ^b,d   Paya, Carlos V ^b  

^a Mayo Clinic   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MAYO CLINIC   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CD14 ANTIGEN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LIGAND; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL STRAIN HEK293; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; HUMAN; HUMAN CELL; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WILD TYPE;

AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; CELL LINE; CHEMOKINES; CYTOKINES; HUMANS; MEMBRANE GLYCOPROTEINS; MONOCYTES; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTORS;

EID: 16244421044     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.4.1617-1621.2005     Document Type: Article

References (15)

1. Arning, M., K. O. Kliche, A. H. Heer-Sonderhoff, and A. Wehmeier. 1995. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38:459-465.
2. Blau, I. W., and A. A. Fauser. 2000. Review of comparative studies between conventional and liposomal amphotericin B (Ambisome) in neutropenic patients with fever of unknown origin and patients with systemic mycosis. Mycoses 43:325-332.
3. Cleary, J. D., S. W. Chapman, and R. L. Nolan. 1992. Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob. Agents Chemother. 36:977-981.
4. Legrand, P., A. Vertut-Doi, and J. Bolard. 1996. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J. Antimicrob. Chemother. 37:519-533.
5. Mehta, J. 1997. Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations? Leukoc. Res. 21:183-188.
6. Mehta, R., G. Lopez-Berestein, R. Hopfer, K. Mills, and R. L. Juliano. 1984. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim. Biophys. Acta 770:230-234.
7. Ozinsky, A., D. M. Underhill, J. D. Fontenot, A. M. Hajjar, K. D. Smith, C. B. Wilson, L. Schroeder, and A. Aderem. 2000. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl. Acad. Sci. USA 97:13766-13771.
8. Perkins, W. R., S. R. Minchey, L. T. Boni, C. E. Swenson, M. C. Popescu, R. F. Pasternack, and A. S. Janoff. 1992. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim. Biophys. Acta 1107:271-282.
9. Prentice, H. G., I. M. Hann, R. Herbrecht, M. Aoun, S. Kvaloy, D. Catovsky, C. R. Pinkerton, S. A. Schey, F. Jacobs, A. Oakhill, R. F. Stevens, P. J. Darbyshire, and B. E. Gibson. 1997. A randomized comparison of liposomal versus conventional amphotericin B for ehe treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. 98:711-718.
10. Rogers, P. D., J. K. Jenkins, S. W. Chapman, K. Ndebele, B. A. Chapman, and J. D. Cleary. 1998. Amphotericin B activation of human genes encoding for cytokines. J. Infect. Dis. 178:1726-1733.
11. Sandor, F., E. Latz, F. Re, L. Mandell, G. Repik, D. T. Golenbock, T. Espevik, E. A. Kurt-Jones, and R. W. Finberg. 2003. Importance of extra- and intracellular domains of TLR1 and TLR2 in NFkappa B signaling. J. Cell Biol. 162:1099-1110.
12. Sau, K., S. S. Mambula, E. Latz, P. Henneke, D. T. Golenbock, and S. M. Levitz. 2003. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J. Biol. Chem. 278:37561-37568.
13. Takeda, K., O. Takeuchi, and S. Akira. 2002. Recognition of lipopeptides by Toll-like receptors. J. Endotoxin Res. 8:459-463.
14. Tiphine, M., V. Letscher-Bru, and R. Herbrecht. 1999. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl. Infect. Dis. 1:273-283.
15. Trejo, W. H., and R. E. Bennett. 1963. Streptomyces nodosus sp. n., the amphotericin-producing organism. J. Bacteriol. 85:436-439.